Financing ·
Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, closing on September 15, to…
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, closing on September 15, to raise approximately $2.5 million in gross proceeds through a private placement of pre-funded warrants and accompanying Series C and D warrants. The company issued 3,105,591 pre-funded warrants at a combined price of $0.804 per unit with the common warrants exercisable at $0.805 per share. Proceeds are designated for working capital and general corporate purposes. This transaction represents significant new financing for the biotechnology company.